author-photo

Michel Delforge

Katholieke Universiteit Leuven
Universitaire Ziekenhuizen Leuven

415

Papers

8560

Citations

Citation Trend

Filter By

Papers (415) Sort By

Journal Conference Others

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (ciltacel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322].

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (46)
CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.

2021 Expert Review of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
P-162: Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)